MedTrace Logo

FAAH Inhibitor Trial for Adults With Tourette Syndrome

NCT02134080 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-10-29

No results posted yet for this study

Summary

The purpose of this trial is to examine the safety, tolerability and feasibility in the use of a FAAH inhibitor for the treatment of adults with Tourette syndrome.

Conditions

  • Tourette Syndrome

Interventions

DRUG

PF-04457845

PF-04457845 will be administered orally at 4mg daily for four weeks.

DRUG

Placebo

Placebo will be administered orally at 4mg daily for four weeks.

Sponsors & Collaborators

  • Tourette Association of America

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Michael H. Bloch, MD, MS · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02134080 on ClinicalTrials.gov